scPharmaceuticals (SCPH) is planning to raise $96 million in an initial public offering (IPO) on Friday, November 17th, IPO Scoop reports. The company plans to issue 6,400,000 shares at a price of $14.00-$16.00 per share.

scPharmaceuticals has a market cap of $264.2 million.

Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

scPharmaceuticals provided the following description of their company for its IPO: “We are a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs. Our proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, we believe our technology reduces overall healthcare costs and advances the quality and convenience of care. Our lead product candidate, Furoscix, consists of our patented subcutaneous formulation of furosemide delivered via our sc2Wear Infusor and is under development for treatment of worsening, or decompensated, heart failure outside of the inpatient setting. We filed a new drug application, or NDA, for Furoscix, with the U.S. Food and Drug Administration, or FDA, in August 2017. “.

scPharmaceuticals was founded in 2013 and has 28 employees. The company is located at 2400 District Avenue, Suite 310, Burlington, MA 01830, US and can be reached via phone at (617) 517-0730 or on the web at

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with's FREE daily email newsletter.